Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration.
Journal
Addiction science & clinical practice
ISSN: 1940-0640
Titre abrégé: Addict Sci Clin Pract
Pays: England
ID NLM: 101316917
Informations de publication
Date de publication:
25 05 2023
25 05 2023
Historique:
received:
29
07
2022
accepted:
15
03
2023
medline:
29
5
2023
pubmed:
26
5
2023
entrez:
25
5
2023
Statut:
epublish
Résumé
BACKGROUND\OBJECTIVES: Concomitant with low rates of pharmacotherapy for incarcerated individuals with OUD, there is a high rate of opioid overdose following re-entry into the community. Our research objective was to develop a better understanding of the factors that influence health-related quality-of-life (HRQoL) among this population during the high-risk transition period from incarceration to community. Few studies have assessed health-related quality-of-life (HRQoL) among individuals with OUD who are involved with the criminal-legal system, let alone over the period directly surrounding release from incarceration. Secondary longitudinal analysis of data from a clinical trial where participants were randomized 1:1 to pre-release extended-release naltrexone (XR-NTX) + referral to community XR-NTX, vs. referral only. We conducted individual, multivariable regressions of EQ-5D domains (mobility, pain/discomfort, anxiety/depression; usual activities and self-care were excluded due to insufficient variation in scores), and the overall preference/utility score. HRQoL data were subset to timepoints immediately before release (baseline) and 12 weeks post-release; treatment groups were collapsed across condition. Multiple imputation by chained equations was conducted to handle missing 3-month data in the dependent variables and covariates, ad hoc. Greater severity in the psychiatric composite score was associated with substantially lower HRQoL, across all measures, following release from incarceration. Greater severity in the medical composite score was associated with lower pain/discomfort-related HRQoL. Our findings highlight the importance of ensuring individuals with OUD are linked not only to MOUD, but also treatment for their comorbid conditions upon release from incarceration.
Identifiants
pubmed: 37231479
doi: 10.1186/s13722-023-00375-0
pii: 10.1186/s13722-023-00375-0
pmc: PMC10210389
doi:
Substances chimiques
Narcotic Antagonists
0
Delayed-Action Preparations
0
Naltrexone
5S6W795CQM
Banques de données
ClinicalTrials.gov
['NCT02617628']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
34Subventions
Organisme : NIDA NIH HHS
ID : P30 DA040500
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA046721
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Addict Behav. 2011 Jan-Feb;36(1-2):79-86
pubmed: 20864261
Psychiatry Res. 2019 Sep;279:237-243
pubmed: 30876731
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
J Nerv Ment Dis. 1980 Jan;168(1):26-33
pubmed: 7351540
J Subst Abuse Treat. 2017 Jun;77:26-30
pubmed: 28476267
Drug Alcohol Depend. 2020 Oct 1;215:108221
pubmed: 32777692
Addiction. 2015 Jun;110(6):1008-14
pubmed: 25703440
Drug Alcohol Depend. 2009 Jan 1;99(1-3):222-30
pubmed: 18930603
BMC Psychiatry. 2012 Aug 15;12:111
pubmed: 22894706
Am J Addict. 2015 Jun;24(4):308-14
pubmed: 25808055
J Chin Med Assoc. 2015 May;78(5):292-8
pubmed: 25732869
Addiction. 2008 Aug;103(8):1320-9; discussion 1330-2
pubmed: 18397359
Qual Life Res. 2020 Dec;29(12):3333-3342
pubmed: 32766941
Value Health. 2019 Aug;22(8):931-941
pubmed: 31426935
J Subst Abuse Treat. 2021 Aug;127:108355
pubmed: 34134881
Am J Public Health. 2009 Apr;99(4):666-72
pubmed: 19150898
Biomed Res Int. 2014;2014:274804
pubmed: 25093161
Addiction. 2010 Sep;105(9):1616-24
pubmed: 20626379
J Child Adolesc Ment Health. 2014;26(1):35-47
pubmed: 25391569
Addiction. 2017 Aug;112(8):1440-1450
pubmed: 28239984
Drug Alcohol Depend. 2001 Jan 1;61(2):195-206
pubmed: 11137285
Epidemiol Rev. 2022 Dec 21;44(1):67-77
pubmed: 36104860
Drug Alcohol Depend. 2017 Mar 01;172:34-42
pubmed: 28107680
Am J Epidemiol. 2009 May 1;169(9):1133-9
pubmed: 19318618
J Subst Abuse Treat. 2022 Oct;141:108835
pubmed: 35933942
N Engl J Med. 2007 Jan 11;356(2):157-65
pubmed: 17215533
Lancet. 2018 Jan 27;391(10118):309-318
pubmed: 29150198
N Engl J Med. 2016 Mar 31;374(13):1232-42
pubmed: 27028913
Int J Methods Psychiatr Res. 2011 Mar;20(1):40-9
pubmed: 21499542
Addiction. 2011 Mar;106(3):507-15
pubmed: 21205046
Drug Alcohol Depend. 2007 Dec 1;91(2-3):220-7
pubmed: 17628351
JAMA. 2015 Nov 10;314(18):1966-7
pubmed: 26547468
Adm Policy Ment Health. 2016 Mar;43(2):207-18
pubmed: 25663094
JAMA Netw Open. 2018 Jul 6;1(3):e180558
pubmed: 30646016
J Subst Abuse Treat. 2018 Feb;85:45-48
pubmed: 28527855
Addiction. 2016 Apr;111(4):675-84
pubmed: 26498740
J Subst Abuse Treat. 2009 Oct;37(3):277-85
pubmed: 19339140
Pain Med. 2011 Apr;12(4):657-67
pubmed: 21392250
Pharmacoeconomics. 2016 Sep;34(9):863-87
pubmed: 27002518
Value Health. 2021 Jul;24(7):1068-1083
pubmed: 34243831
Public Health Rev. 2014;35(2):
pubmed: 28366975
Neuropsychol Rev. 2007 Sep;17(3):299-315
pubmed: 17690984
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
J Psychoactive Drugs. 2013 Sep-Oct;45(4):304-12
pubmed: 24377169
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
Drug Alcohol Depend. 2014 Sep 1;142:33-40
pubmed: 24962326